Abiomed’s Impella Cardiac Pump Needs PMA Study, FDA Panel Says
This article was originally published in The Gray Sheet
Executive Summary
Better data is needed in the form of a PMA study to assess the safety and effectiveness of Abiomed’s flagship Impella 2.5 blood pump, advisory panel recommends.